TUMOUR MARKER IN BRCA2 ASSOCIATED BREAST CANCER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Dec 10, 2007
filing date -
Jun 10, 2005
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to a diagnostic method for diagnosing the possible recurrence of breast cancer, wherein the presence of the monoclonal antibody CA-125 is monitored in a BRCA2 tumor sample, whereby any presence of CA-125 is indicative of metastazing BRCA2. The invention also relates to the use of monoclonal antibody CA-125, or monoclonal antibody oregovo monoclonal antibody in the preparation of a therapeutic composition for the treatment of breast cancer of the BRCA2 type.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully